Plasma phosphorylated tau181 (P-tau181) might be increased in Alzheimer’s disease (AD),
but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P-…

Introduction We studied whether fully automated Elecsys cerebrospinal fluid (CSF)
immunoassay results were concordant with positron emission tomography (PET) and predicted …

Importance Blood-based tests for brain amyloid-β (Aβ) pathology are needed for widespread
implementation of Alzheimer disease (AD) biomarkers in clinical care and to facilitate …

Importance Accurate blood-based biomarkers for Alzheimer disease (AD) might improve the
diagnostic accuracy in primary care, referrals to memory clinics, and screenings for AD trials…

Introduction Available assays for quantitation of the Alzheimer's disease (AD) biomarker
amyloid-beta 1–42 (Aβ [1–42]) in cerebrospinal fluid demonstrate significant variability and lack …

Failures in Alzheimer's disease ( AD ) drug trials highlight the need to further explore disease
mechanisms and alterations of biomarkers during the development of AD . Using cross‐…

Importance Alzheimer disease (AD), a neurodegenerative disease characterized by β-amyloid
plaques and τ tangles in the brain, represents an unmet medical need with no fully …

We evaluated the performance of CSF biomarkers for predicting risk of clinical decline and
conversion to dementia in non-demented patients with cognitive symptoms. CSF samples …

Introduction There is a great need for fully automated plasma assays that can measure amyloid
beta (Aβ) pathology and predict future Alzheimer's disease (AD) dementia. Methods Two …

Background and Objectives To determine how fully automated Elecsys CSF immunoassays
for β-amyloid (Aβ) and tau biomarkers and an ultrasensitive Simoa assay for neurofilament …